Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MiCADO: Metronomic Capecitabine and Docetaxel in Advanced Gastric Cancer
NCT02007148Phase 2Unknown
- Sponsor
- International Group of Endovascular Oncology
- Start
- Nov 2013
- Primary completion
- Oct 2021
- Modality
- DNA Intercalators/Alkylators, Irreversible Covalent Inhibitors, RNA-Targeting Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of capecitabine in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma, sponsored by International Group of Endovascular Oncology. Status: unknown.
02
Drugs
capecitabine
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinoma
Beyond the preview
Go deeper on NCT02007148.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02007148.